Autoimmune pancreatitis medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Autoimmune pancreatitis}} {{CMG}}; {{AE}} ==Overview== There is no treatment for [disease name]; the mainstay of therapy is supportive care. OR Supportive thera...")
 
 
(20 intermediate revisions by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Autoimmune pancreatitis}}
{{Autoimmune pancreatitis}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}{{IQ}}


==Overview==
==Overview==
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
[[Glucocorticoids]] are found to play an important role in the management of autoimmune pancreatitis via several ways such as efficacy in alleviating symptoms, decreasing the size of the [[pancreas]], reversing histopathologic features in patients with AIP,  and mprovement of lab findings. About 2/3rd of patients show good response to [[glucocorticoids]] with complete recovery, 25% may require a second course of [[glucocorticoids]], and a few patients with autoimmune pancreatitis may require continuous treatment. [[Immunomodulatory]] drugs such as [[azathioprine]] are usually used when, AIP patients have no response to [[steroid]] management, [[relapse]] occurs and patients cannot be weaned off [[steroids]].


OR
==Medical Therapy==
 
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
 
OR
 
The majority of cases of [disease name] are self-limited and require only supportive care.
 
OR
 
[Disease name] is a medical emergency and requires prompt treatment.


OR
=== Role of Glucocorticoids: ===
* Preferred regimen: [[Prednisone]] is usually administered at an initial dose of 40 mg/d for 4 weeks followed by a taper of the daily dosage by 5 mg/wk depending upon the clinical parameters.


The mainstay of treatment for [disease name] is [therapy].
*[[Glucocorticoids]] are found to play an important role in the management of autoimmune pancreatitis via several ways such as:<ref name="pmid14687819">{{cite journal |vauthors=Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N |title=Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma |journal=Am. J. Gastroenterol. |volume=98 |issue=12 |pages=2694–9 |year=2003 |pmid=14687819 |doi=10.1111/j.1572-0241.2003.08775.x |url=}}</ref><ref name="pmid17525092">{{cite journal |vauthors=Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, Nakai Y, Sasahira N, Tsujino T, Yoshida H, Kawabe T, Omata M |title=Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment |journal=Gut |volume=56 |issue=12 |pages=1719–24 |year=2007 |pmid=17525092 |pmc=2095691 |doi=10.1136/gut.2006.115246 |url=}}</ref><ref name="pmid18583399">{{cite journal |vauthors=Moon SH, Kim MH, Park DH, Hwang CY, Park SJ, Lee SS, Seo DW, Lee SK |title=Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study |journal=Gut |volume=57 |issue=12 |pages=1704–12 |year=2008 |pmid=18583399 |doi=10.1136/gut.2008.150979 |url=}}</ref><ref name="pmid9246047">{{cite journal |vauthors=Ito T, Nakano I, Koyanagi S, Miyahara T, Migita Y, Ogoshi K, Sakai H, Matsunaga S, Yasuda O, Sumii T, Nawata H |title=Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy |journal=Dig. Dis. Sci. |volume=42 |issue=7 |pages=1458–68 |year=1997 |pmid=9246047 |doi= |url=}}</ref>
 
**Efficacy in alleviating symptoms.
OR
**Decreasing the size of the pancreas.
 
**Reversing histopathologic features in patients with AIP.
The optimal therapy for [malignancy name] depends on the stage at diagnosis.
**Improvement of lab findings such as:<ref name="pmid11236777">{{cite journal |vauthors=Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, Fukushima M, Nikaido T, Nakayama K, Usuda N, Kiyosawa K |title=High serum IgG4 concentrations in patients with sclerosing pancreatitis |journal=N. Engl. J. Med. |volume=344 |issue=10 |pages=732–8 |year=2001 |pmid=11236777 |doi=10.1056/NEJM200103083441005 |url=}}</ref>
 
***Resolution of [[hypergammaglobulinemia]].
OR
***[[Autoantibodies]] become undetectable.
 
[Therapy] is recommended among all patients who develop [disease name].
 
OR
 
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
 
OR
 
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
 
OR
 
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
 
OR
 
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
 
==Medical Therapy==
*Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
*Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
*Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
===Disease Name===


* '''1 Stage 1 - Name of stage'''
===== Response to Glucocorticoids: =====
** 1.1 '''Specific Organ system involved 1'''
* About 2/3rd of patients show good response to [[glucocorticoids]] with complete recovery.<ref name="pmid18222442">{{cite journal |vauthors=Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, Topazian MD, Clain JE, Pearson RK, Petersen BT, Vege SS, Lindor K, Farnell MB |title=Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy |journal=Gastroenterology |volume=134 |issue=3 |pages=706–15 |year=2008 |pmid=18222442 |doi=10.1053/j.gastro.2007.12.009 |url=}}</ref><ref name="pmid19532132">{{cite journal |vauthors=Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M, Whitcomb DC, Slivka A |title=Evaluation and management of autoimmune pancreatitis: experience at a large US center |journal=Am. J. Gastroenterol. |volume=104 |issue=9 |pages=2295–306 |year=2009 |pmid=19532132 |doi=10.1038/ajg.2009.325 |url=}}</ref><ref name="pmid19345283">{{cite journal |vauthors=Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, Deheragoda MG, Novelli M, Winstanley A, Rodriguez-Justo M, Hatfield AR, Pereira SP, Webster GJ |title=Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis |journal=Clin. Gastroenterol. Hepatol. |volume=7 |issue=10 |pages=1089–96 |year=2009 |pmid=19345283 |doi=10.1016/j.cgh.2009.03.021 |url=}}</ref>
*** 1.1.1 '''Adult'''
* Approximately 25% may require a second course of [[glucocorticoids]].
**** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' 
* A few patients with autoimmune pancreatitis may require continuous treatment.
**** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
**** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
**** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
**** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
**** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
*** 1.1.2 '''Pediatric'''
**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose) 
***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
****1.1.2.2 (Specific population e.g. ''''''children < 8 years of age'''''')
***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose) 
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
** 1.2 '''Specific Organ system involved 2'''
*** 1.2.1 '''Adult'''
**** Preferred regimen (1): [[drug name]] 500 mg PO q8h
*** 1.2.2  '''Pediatric'''
**** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)


* 2 '''Stage 2 - Name of stage'''
==== Response to Glucocorticoids in patients with Biliary strictures: ====
** 2.1 '''Specific Organ system involved 1 '''
Patients with biliary strictures have a variable response to [[glucocorticoids]] such as:<ref name="pmid18222442">{{cite journal |vauthors=Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, Topazian MD, Clain JE, Pearson RK, Petersen BT, Vege SS, Lindor K, Farnell MB |title=Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy |journal=Gastroenterology |volume=134 |issue=3 |pages=706–15 |year=2008 |pmid=18222442 |doi=10.1053/j.gastro.2007.12.009 |url=}}</ref><ref name="pmid19345283">{{cite journal |vauthors=Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, Deheragoda MG, Novelli M, Winstanley A, Rodriguez-Justo M, Hatfield AR, Pereira SP, Webster GJ |title=Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis |journal=Clin. Gastroenterol. Hepatol. |volume=7 |issue=10 |pages=1089–96 |year=2009 |pmid=19345283 |doi=10.1016/j.cgh.2009.03.021 |url=}}</ref><ref name="pmid16843735">{{cite journal |vauthors=Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, Clain JE, Pearson RK, Petersen BT, Vege SS, Farnell MB |title=Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience |journal=Clin. Gastroenterol. Hepatol. |volume=4 |issue=8 |pages=1010–6; quiz 934 |year=2006 |pmid=16843735 |doi=10.1016/j.cgh.2006.05.017 |url=}}</ref><ref name="pmid15545176">{{cite journal |vauthors=Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A |title=Morphological changes after steroid therapy in autoimmune pancreatitis |journal=Scand. J. Gastroenterol. |volume=39 |issue=11 |pages=1154–8 |year=2004 |pmid=15545176 |doi=10.1080/00365520410008033 |url=}}</ref><ref name="pmid15632697">{{cite journal |vauthors=Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N |title=Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment |journal=Pancreas |volume=30 |issue=1 |pages=31–9 |year=2005 |pmid=15632697 |doi= |url=}}</ref>
**: '''Note (1):'''
* Patients with biliary strictures may respond to [[glucocorticoids]].
**: '''Note (2)''':  
* Patients with biliary strictures may not respond to [[glucocorticoids]].
**: '''Note (3):'''
* Patients with biliary strictures may have an incomplete response to [[glucocorticoids]].
*** 2.1.1 '''Adult'''
* Patients with biliary strictures may require maintenance therapy with [[glucocorticoids]] to prevent relapse.
**** Parenteral regimen
* Patients with biliary strictures may require maintenance therapy with [[glucocorticoids]] and/or [[immunomodulatory]] drugs  to prevent [[relapse]].
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
====== Monitoring of clinical parameters in patients on glucocorticoid therapy: ======
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
[[Glucocorticoids]] are tapered depending upon following clinical parameters:<ref name="pmid17525092">{{cite journal |vauthors=Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, Nakai Y, Sasahira N, Tsujino T, Yoshida H, Kawabe T, Omata M |title=Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment |journal=Gut |volume=56 |issue=12 |pages=1719–24 |year=2007 |pmid=17525092 |pmc=2095691 |doi=10.1136/gut.2006.115246 |url=}}</ref><ref name="pmid18583399">{{cite journal |vauthors=Moon SH, Kim MH, Park DH, Hwang CY, Park SJ, Lee SS, Seo DW, Lee SK |title=Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study |journal=Gut |volume=57 |issue=12 |pages=1704–12 |year=2008 |pmid=18583399 |doi=10.1136/gut.2008.150979 |url=}}</ref><ref name="pmid20736934">{{cite journal |vauthors=Maire F, Le Baleur Y, Rebours V, Vullierme MP, Couvelard A, Voitot H, Sauvanet A, Hentic O, Lévy P, Ruszniewski P, Hammel P |title=Outcome of patients with type 1 or 2 autoimmune pancreatitis |journal=Am. J. Gastroenterol. |volume=106 |issue=1 |pages=151–6 |year=2011 |pmid=20736934 |doi=10.1038/ajg.2010.314 |url=}}</ref><ref name="pmid19017924">{{cite journal |vauthors=Sahani DV, Sainani NI, Deshpande V, Shaikh MS, Frinkelberg DL, Fernandez-del Castillo C |title=Autoimmune pancreatitis: disease evolution, staging, response assessment, and CT features that predict response to corticosteroid therapy |journal=Radiology |volume=250 |issue=1 |pages=118–29 |year=2009 |pmid=19017924 |doi=10.1148/radiol.2493080279 |url=}}</ref>
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
* Relief of symptoms.
**** Oral regimen
* Serial changes in abdominal imaging of the pancreas and bile ducts.
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
* Decreased serum γ-globulin and IgG4 levels.
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
* Improvements in liver function tests.
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
=== Role of Immunomodulatory drugs: ===
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
[[Immunomodulatory]] drugs such as [[azathioprine]] are usually used when:
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
* AIP patients have no response to [[steroid]] management.
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
* AIP patients relapse, if [[steroids]] are discontinued.
*** 2.1.2 '''Pediatric'''
* AIP patients cannot be weaned off [[steroids]].
**** Parenteral regimen
The [[monoclonal antibody]], [[Rituximab]], is found to be effective in the management of AIP but further studies are required for the recommendation of routine use.<ref name="pmid22936672">{{cite journal |vauthors=Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, Levy MJ, Pearson RK, Petersen BT, Smyrk TC, Sugumar A, Takahashi N, Vege SS, Chari ST |title=Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience |journal=Gut |volume=62 |issue=11 |pages=1607–15 |year=2013 |pmid=22936672 |doi=10.1136/gutjnl-2012-302886 |url=}}</ref><ref name="pmid18328441">{{cite journal |vauthors=Topazian M, Witzig TE, Smyrk TC, Pulido JS, Levy MJ, Kamath PS, Chari ST |title=Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis |journal=Clin. Gastroenterol. Hepatol. |volume=6 |issue=3 |pages=364–6 |year=2008 |pmid=18328441 |doi=10.1016/j.cgh.2007.12.020 |url=}}</ref><ref name="pmid19137434">{{cite journal |vauthors=Rueda JC, Duarte-Rey C, Casas N |title=Successful treatment of relapsing autoimmune pancreatitis in primary Sjögren's syndrome with rituximab: report of a case and review of the literature |journal=Rheumatol. Int. |volume=29 |issue=12 |pages=1481–5 |year=2009 |pmid=19137434 |doi=10.1007/s00296-009-0843-5 |url=}}</ref>
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) ''''''(Contraindications/specific instructions)''''''
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
** 2.2  '<nowiki/>'''''Other Organ system involved 2''''''
**: '''Note (1):'''
**: '''Note (2)''':
**: '''Note (3):'''
*** 2.2.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
*** 2.2.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)


==References==
==References==

Latest revision as of 15:32, 19 January 2018

Autoimmune pancreatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune pancreatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines for Management

Case Studies

Case #1

Autoimmune pancreatitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune pancreatitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune pancreatitis medical therapy

CDC on Autoimmune pancreatitis medical therapy

Autoimmune pancreatitis medical therapy in the news

Blogs on Autoimmune pancreatitis medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Autoimmune pancreatitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2]

Overview

Glucocorticoids are found to play an important role in the management of autoimmune pancreatitis via several ways such as efficacy in alleviating symptoms, decreasing the size of the pancreas, reversing histopathologic features in patients with AIP, and mprovement of lab findings. About 2/3rd of patients show good response to glucocorticoids with complete recovery, 25% may require a second course of glucocorticoids, and a few patients with autoimmune pancreatitis may require continuous treatment. Immunomodulatory drugs such as azathioprine are usually used when, AIP patients have no response to steroid management, relapse occurs and patients cannot be weaned off steroids.

Medical Therapy

Role of Glucocorticoids:

  • Preferred regimen: Prednisone is usually administered at an initial dose of 40 mg/d for 4 weeks followed by a taper of the daily dosage by 5 mg/wk depending upon the clinical parameters.
  • Glucocorticoids are found to play an important role in the management of autoimmune pancreatitis via several ways such as:[1][2][3][4]
    • Efficacy in alleviating symptoms.
    • Decreasing the size of the pancreas.
    • Reversing histopathologic features in patients with AIP.
    • Improvement of lab findings such as:[5]
Response to Glucocorticoids:
  • About 2/3rd of patients show good response to glucocorticoids with complete recovery.[6][7][8]
  • Approximately 25% may require a second course of glucocorticoids.
  • A few patients with autoimmune pancreatitis may require continuous treatment.

Response to Glucocorticoids in patients with Biliary strictures:

Patients with biliary strictures have a variable response to glucocorticoids such as:[6][8][9][10][11]

Monitoring of clinical parameters in patients on glucocorticoid therapy:

Glucocorticoids are tapered depending upon following clinical parameters:[2][3][12][13]

  • Relief of symptoms.
  • Serial changes in abdominal imaging of the pancreas and bile ducts.
  • Decreased serum γ-globulin and IgG4 levels.
  • Improvements in liver function tests.

Role of Immunomodulatory drugs:

Immunomodulatory drugs such as azathioprine are usually used when:

  • AIP patients have no response to steroid management.
  • AIP patients relapse, if steroids are discontinued.
  • AIP patients cannot be weaned off steroids.

The monoclonal antibody, Rituximab, is found to be effective in the management of AIP but further studies are required for the recommendation of routine use.[14][15][16]

References

  1. ↑ Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N (2003). "Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma". Am. J. Gastroenterol. 98 (12): 2694–9. doi:10.1111/j.1572-0241.2003.08775.x. PMID 14687819.
  2. ↑ 2.0 2.1 Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, Nakai Y, Sasahira N, Tsujino T, Yoshida H, Kawabe T, Omata M (2007). "Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment". Gut. 56 (12): 1719–24. doi:10.1136/gut.2006.115246. PMC 2095691. PMID 17525092.
  3. ↑ 3.0 3.1 Moon SH, Kim MH, Park DH, Hwang CY, Park SJ, Lee SS, Seo DW, Lee SK (2008). "Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study". Gut. 57 (12): 1704–12. doi:10.1136/gut.2008.150979. PMID 18583399.
  4. ↑ Ito T, Nakano I, Koyanagi S, Miyahara T, Migita Y, Ogoshi K, Sakai H, Matsunaga S, Yasuda O, Sumii T, Nawata H (1997). "Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy". Dig. Dis. Sci. 42 (7): 1458–68. PMID 9246047.
  5. ↑ Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, Fukushima M, Nikaido T, Nakayama K, Usuda N, Kiyosawa K (2001). "High serum IgG4 concentrations in patients with sclerosing pancreatitis". N. Engl. J. Med. 344 (10): 732–8. doi:10.1056/NEJM200103083441005. PMID 11236777.
  6. ↑ 6.0 6.1 Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, Topazian MD, Clain JE, Pearson RK, Petersen BT, Vege SS, Lindor K, Farnell MB (2008). "Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy". Gastroenterology. 134 (3): 706–15. doi:10.1053/j.gastro.2007.12.009. PMID 18222442.
  7. ↑ Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M, Whitcomb DC, Slivka A (2009). "Evaluation and management of autoimmune pancreatitis: experience at a large US center". Am. J. Gastroenterol. 104 (9): 2295–306. doi:10.1038/ajg.2009.325. PMID 19532132.
  8. ↑ 8.0 8.1 Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, Deheragoda MG, Novelli M, Winstanley A, Rodriguez-Justo M, Hatfield AR, Pereira SP, Webster GJ (2009). "Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis". Clin. Gastroenterol. Hepatol. 7 (10): 1089–96. doi:10.1016/j.cgh.2009.03.021. PMID 19345283.
  9. ↑ Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, Clain JE, Pearson RK, Petersen BT, Vege SS, Farnell MB (2006). "Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience". Clin. Gastroenterol. Hepatol. 4 (8): 1010–6, quiz 934. doi:10.1016/j.cgh.2006.05.017. PMID 16843735.
  10. ↑ Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A (2004). "Morphological changes after steroid therapy in autoimmune pancreatitis". Scand. J. Gastroenterol. 39 (11): 1154–8. doi:10.1080/00365520410008033. PMID 15545176.
  11. ↑ Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N (2005). "Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment". Pancreas. 30 (1): 31–9. PMID 15632697.
  12. ↑ Maire F, Le Baleur Y, Rebours V, Vullierme MP, Couvelard A, Voitot H, Sauvanet A, Hentic O, Lévy P, Ruszniewski P, Hammel P (2011). "Outcome of patients with type 1 or 2 autoimmune pancreatitis". Am. J. Gastroenterol. 106 (1): 151–6. doi:10.1038/ajg.2010.314. PMID 20736934.
  13. ↑ Sahani DV, Sainani NI, Deshpande V, Shaikh MS, Frinkelberg DL, Fernandez-del Castillo C (2009). "Autoimmune pancreatitis: disease evolution, staging, response assessment, and CT features that predict response to corticosteroid therapy". Radiology. 250 (1): 118–29. doi:10.1148/radiol.2493080279. PMID 19017924.
  14. ↑ Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, Levy MJ, Pearson RK, Petersen BT, Smyrk TC, Sugumar A, Takahashi N, Vege SS, Chari ST (2013). "Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience". Gut. 62 (11): 1607–15. doi:10.1136/gutjnl-2012-302886. PMID 22936672.
  15. ↑ Topazian M, Witzig TE, Smyrk TC, Pulido JS, Levy MJ, Kamath PS, Chari ST (2008). "Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis". Clin. Gastroenterol. Hepatol. 6 (3): 364–6. doi:10.1016/j.cgh.2007.12.020. PMID 18328441.
  16. ↑ Rueda JC, Duarte-Rey C, Casas N (2009). "Successful treatment of relapsing autoimmune pancreatitis in primary Sjögren's syndrome with rituximab: report of a case and review of the literature". Rheumatol. Int. 29 (12): 1481–5. doi:10.1007/s00296-009-0843-5. PMID 19137434.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Autoimmune_pancreatitis_medical_therapy&oldid=1431067"